Extramedullary involvement of B-cell Acute Lymphoblastic Leukemia (EM-ALL) is a rare occurrence, characterized by dismal outcome and the absence of a defined and shared therapeutic approach. In the landscape of innovative compounds, inotuzumab ozogamicin (IO) is a promising drug, whose mechanism of action relies on the killing of CD22 positive leukemic cells, through the delivery, after cell binding, of a molecule of calicheamicin.

Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia

Bertamini, Luca;Nanni, Jacopo;Marconi, Giovanni;Abbenante, Mariachiara;Robustelli, Valentina;Matti, Antonella;Paolini, Stefania;Sartor, Chiara;Monaco, Silvia Lo;Fontana, Maria Chiara;Cavo, Michele;Curti, Antonio;Martinelli, Giovanni;Papayannidis, Cristina
2018

Abstract

Extramedullary involvement of B-cell Acute Lymphoblastic Leukemia (EM-ALL) is a rare occurrence, characterized by dismal outcome and the absence of a defined and shared therapeutic approach. In the landscape of innovative compounds, inotuzumab ozogamicin (IO) is a promising drug, whose mechanism of action relies on the killing of CD22 positive leukemic cells, through the delivery, after cell binding, of a molecule of calicheamicin.
Bertamini, Luca; Nanni, Jacopo; Marconi, Giovanni; Abbenante, Mariachiara; Robustelli, Valentina; Bacci, Francesco; Matti, Antonella; Paolini, Stefania; Sartor, Chiara; Monaco, Silvia Lo; Fontana, Maria Chiara; De Polo, Stefano; Cavo, Michele; Curti, Antonio; Martinelli, Giovanni; Papayannidis, Cristina
File in questo prodotto:
File Dimensione Formato  
s12885-018-5026-x.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 1 MB
Formato Adobe PDF
1 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/670713
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 10
social impact